Coya Therapeutics, Inc. (COYA)

Coya Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	35.99	32.63	5.93	4.34
Cash & Cash Equivalents	35.99	32.63	5.93	4.34
Cash Growth	120.52%	449.86%	36.72%	-
Receivables	0	7.5	0	0
Other Current Assets	1.34	1.07	1.25	0.24
Total Current Assets	37.33	41.2	7.18	4.58
Property, Plant & Equipment	0.06	0.07	0.09	0.12
Other Long-Term Assets	0	0	1.12	0.09
Total Long-Term Assets	0.06	0.07	1.21	0.21
Total Assets	37.39	41.26	8.4	4.79
Accounts Payable	1.59	1.16	1.82	0.86
Deferred Revenue	1.37	1.5	0	0
Other Current Liabilities	1.36	2.4	2.01	0.29
Total Current Liabilities	4.32	5.05	3.82	1.15
Long-Term Debt	0	0	12.97	0
Other Long-Term Liabilities	0.68	0.57	0	0
Total Long-Term Liabilities	0.68	0.57	12.97	0
Total Liabilities	5	5.63	16.79	1.15
Total Debt	0	0	12.97	0
Retained Earnings	-30.91	-25.86	-17.87	-5.62
Shareholders' Equity	32.39	35.64	-8.39	3.64
Net Cash / Debt	35.99	32.63	-7.03	4.34
Net Cash / Debt Growth	120.52%	-	-	-
Net Cash Per Share	2.49	3.21	-2.71	1.68
Working Capital	33.02	36.14	3.36	3.44
Book Value Per Share	2.24	3.51	-3.24	1.41

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).